Cleaved-Factor XII HC (R372) Antibody

BT-AP01926

Rabbit

IgG

20ul,50ul,100ul

Polyclonal

The antiserum was produced against synthesized peptide derived from human FA12. AA range:323-372

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

1 mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

-20°C for one year

F12 encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in F12 do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged.

Human: P00748; Mouse: Q80YC5;

67818

Human: 2161

F12; Coagulation factor XII; Hageman factor; HAF

Cardiovascular

F12